DW1698Z
Brachytherapy Pelvic Region to None with Iridium 192 (Ir-192), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | W Anatomical Regions |
| Operation | 1 Brachytherapy |
| Body Part | 6 Pelvic Region |
| Approach | 9 High Dose Rate (HDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
This family covers brachytherapy, the placement of sealed radioactive sources directly into or next to an anatomical region rather than into a single specifically classified organ. Small radioactive seeds, wires, or applicators are positioned so the radiation dose is concentrated close to the treatment area while sparing surrounding tissue more than external beam methods typically allow.
It's used for regional tumors or postoperative tumor beds where placing the source directly at the site gives better dose control, and sometimes for recurrent disease in a region previously treated with external radiation. The sources may be left temporarily or permanently depending on the isotope and clinical goal, and the procedure is performed by a radiation oncologist, often with imaging guidance to confirm correct placement.
Anatomy & Axis Detail
Pelvic Region
Pelvic brachytherapy places radioactive sources within the pelvic cavity, most classically as intracavitary treatment for cervical or endometrial cancer using a tandem and ovoid or ring applicator inserted through the vagina, or as interstitial implants for prostate, vaginal, or rectal tumors. The technique exploits the pelvis's relatively fixed bony framework to hold applicators in reproducible position across multiple treatment fractions, delivering a steep dose gradient that concentrates radiation at the cervix, prostate, or other pelvic target while sparing the adjacent bladder and rectum. Applicator placement is usually performed under anesthesia with imaging confirmation, and this pelvic region code applies when the treated volume spans the general pelvic cavity rather than a single organ tracked elsewhere, such as the genitourinary tract.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
A code from this family requires documentation naming the anatomical region treated (rather than a specific organ with its own body system) along with the isotope or source type used and whether the implant is temporary or permanent, since these details determine the qualifier. Operative notes describing applicator or seed placement, along with dosimetry records, support the code choice. Coders most often err by coding to Anatomical Regions when the physician's note actually identifies a specific organ that has a dedicated body system, or by missing whether the source was left in place versus removed after treatment, which changes the qualifier selected.
Commonly Confused With
This is frequently confused with Brachytherapy coded to a named body system, such as Gynecological or Urinary, when the treated site is actually a specific organ; the distinguishing factor is whether the note names an organ (use that body system) or describes a regional field or postsurgical bed spanning tissue not tied to one organ (use Anatomical Regions). It also overlaps conceptually with Beam Radiation to the same region, but the presence of an implanted or applied source rather than an external delivery is what separates brachytherapy from beam therapy.